ABSTRACT
Efficacy of 3-12 month use of trimetazidine hydrochloride combined with verapamil was assessed in postmenopausal women with effort angina by repetitive exercise tests, ECG monitoring and echocardiography. The use of trimetazidine was associated with augmentation of antianginal and antiischemic action of verapamil, improvement of systolic and diastolic left ventricular function, decrease in frequency of hospitalizations because of exacerbation of ischemic heart disease. These effects were evident in all age groups throughout the period of observation and did not depend on the ischemic heart disease duration.
Subject(s)
Myocardial Ischemia/drug therapy , Trimetazidine/therapeutic use , Vasodilator Agents/therapeutic use , Verapamil/therapeutic use , Aged , Drug Therapy, Combination , Female , Humans , Middle Aged , Myocardial Ischemia/physiopathology , Postmenopause , Premenopause , Treatment OutcomeABSTRACT
Potentiating ability of piracetam and tocopherol acetate was studied outpatiently in aged patients with ischemic heart disease. It was found that the addition of piracetam and tocopherol acetate to conventional antianginal drug therapy brings higher response and exercise tolerance, contributes to more effective hemodynamic and energetic support of the exercise, to positive changes in the central and peripheral hemodynamics.
Subject(s)
Angina, Unstable/drug therapy , Antioxidants/therapeutic use , Neuroprotective Agents/therapeutic use , Piracetam/therapeutic use , Vitamin E/analogs & derivatives , alpha-Tocopherol/analogs & derivatives , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Aged , Aged, 80 and over , Angina, Unstable/physiopathology , Antioxidants/administration & dosage , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/therapeutic use , Drug Administration Routes , Drug Synergism , Drug Therapy, Combination , Electrocardiography, Ambulatory , Humans , Middle Aged , Neuroprotective Agents/administration & dosage , Piracetam/administration & dosage , Tocopherols , Treatment Outcome , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic use , Vitamin E/administration & dosage , Vitamin E/therapeutic useABSTRACT
160 presenile and senile CHD patients received calcium antagonists nifedipine, verapamil, diltiazem. The highest antianginal effect occurred after a course of verapamil with special effect in those functionally compromised. Rheoencephalographic picture was dependent on the initial functional class of the patient and overall treatment efficacy. The response was associated with low hydrocortisone and thyroxine levels, high glucose tolerance and content of ionized calcium.
Subject(s)
Calcium Channel Blockers/therapeutic use , Hormones/blood , Myocardial Ischemia/drug therapy , Aged , Aged, 80 and over , Exercise Tolerance/drug effects , Female , Hemodynamics/drug effects , Humans , Male , Middle Aged , Myocardial Ischemia/blood , Myocardial Ischemia/physiopathology , Myocardial Ischemia/rehabilitationSubject(s)
Angina Pectoris/drug therapy , Calcium Channel Blockers/therapeutic use , Cardiovascular Agents/therapeutic use , Diltiazem/therapeutic use , Nifedipine/therapeutic use , Vasodilator Agents/therapeutic use , Verapamil/therapeutic use , Age Factors , Aged , Aged, 80 and over , Angina Pectoris/physiopathology , Angina Pectoris/rehabilitation , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/pharmacology , Cardiovascular Agents/administration & dosage , Cardiovascular Agents/pharmacology , Diltiazem/administration & dosage , Diltiazem/pharmacology , Female , Hemodynamics/drug effects , Humans , Male , Middle Aged , Nifedipine/administration & dosage , Nifedipine/pharmacology , Outpatients , Vasodilator Agents/administration & dosage , Vasodilator Agents/pharmacology , Verapamil/administration & dosage , Verapamil/pharmacologyABSTRACT
The clinical and hemodynamic efficiency of piracetam (nootporil) used in the long-term combined therapy of elderly and senile patients with chronic coronary heart diseases was studied outpatiently. This drug led to a significant enhancement of the antianginal effect of the basic treatment, to more regression of clinical signs of chronic circulatory insufficiency, to positive central hemodynamic changes, higher exercise tolerance, lower energy consumption index per performance unit, increased adaptive potential of the circulatory system, and maintained optimal cerebral blood flow.